Technology Appraisal Virtual Committee Meeting

Committee B

Zoom

# Minutes: Confirmed

## Date and Time: Thursday 13 August 2020 09.30am – 5.45pm

### Present:

1. Professor Amanda Adler (Chair) Present for all notes
2. Dr Sanjeev Patel (Vice-Chair) Present for all notes
3. Dr Carlo Berti Present for all notes
4. Mr Mike Chambers Present for all notes
5. Mr Mark Chapman Present for all notes
6. Dr Mark Glover Present for all notes
7. Dr Megan John Present for all notes
8. Professor Sanjay Kinra Present for all notes
9. Dr Veline L'Esperance Present for all notes
10. Ms Stella O’Brien Present for all notes
11. Dr Rhiannon Owen Present for all notes
12. Ms Anna Pracz Present for all notes
13. Dr Stephen Smith Present for all notes
14. Professor Nicky Welton Present for all notes
15. Mr Nigel Westwood Present for all notes
16. Professor Sarah Wild Present for notes 1 to 8
17. Dr Ed Wilson Present for all notes
18. Mr Tony Wootton Present for all notes

### In attendance:

* Nicole Elliott, Associate Director, NICE, Present for all notes
* Joanne Ekeledo, Project Manager, NICE, Present for notes 1 to 8
* Sophie McHugh, Administrator, NICE, Present for notes 9 to 14
* Jeremy Powell, Project Manager, NICE, Present for all notes
* Mira Patel, Administrator, NICE, Present for all notes
* Laura Marsden, Coordinator, NICE, Present for all notes
* Jessica Cronshaw, Technical Analyst, NICE, Present for notes 1 to 8
* Lorna Dunning, Technical Adviser, NICE, Present for notes 1 to 8
* Hannah Nicholas, Technical Analyst, NICE, Present for notes 9 to 14
* Carl Prescott, Technical Adviser, NICE, Present for notes 9 to 14
* Daniel Gallacher, Warwick Evidence, Evidence Review Group, Present for notes 1 to 5
* Yen-Fu Chen, Warwick Evidence, Evidence Review Group, Present for notes 1 to 5
* Ewen Cummins, Warwick Evidence, Evidence Review Group, Present for notes 1 to 5
* Caroline Farmer, PenTAG, Evidence Review Group, Present for notes 9 to 11
* G.J. Melendez-Torres, PenTAG, Evidence Review Group, Present for notes 9 to 11
* Louise Crathorne, PenTAG, Evidence Review Group, Present for notes 9 to 11
* Naureen Starling, Clinical Expert, Consultant Medical Oncologist, Present for notes 1 to 4
* Harpeet Wasan, Clinical Expert, Medical Oncologist, Present for notes 1 to 4
* Deborah James, Patient Expert, Present for notes 1 to 4
* Alexander Salkled, Patient Expert, Present for notes 1 to 4
* Guy Pratt, Clinical Expert, Consultant Haematologist, Present for notes 9 to 10
* Karthik Ramasamy, Clinical Expert, Consultant Haematologist, Present for notes 9 to 10
* Shelagh McKinlay, Patient Expert, Head of Patient Advocacy Myeloma UK, Present for notes 9 to 10
* Steve Billcliffe, Patient Expert, Present for notes 9 to 10
* Prof Peter Clark, Cancer Drugs Fund Clinical Lead, Present for all notes

### Non-public attendees:

* Paul Arundel, NICE HST Vice Chair, Present for all notes
* Helen Barnett, Editor, NICE, Present for all notes
* Claire Hawksworth, Technical Adviser, Managed Access, NICE, Present for all notes
* Peter Jackson, NICE HST Chair, Present for all notes
* Heidi Livingstone, Public Involvement adviser, NICE, Present for notes 1 to 4 and 9 to 10
* Edgar Masanga, NICE, Resource Impact Team, NICE, Present for all notes
* Sharmilla Nebhrajani, NICE Chairman, Present for notes 1 to 8
* Maria Pitan, Corporate Office Project Manager, NICE, Present for notes 1 to 4 and 9 to 10
* Sandra Robinson, Corporate Office Coordinator, NICE, Present for notes 1 to 4 and 9 to 10
* Thomas Strong, Technical Adviser, Managed Access, NICE, Present for all notes

## Notes

### Any other Business

1. None.

### Minutes from the last meeting

1. The committee approved the minutes of the committee meeting held on Thursday 16 July 2020.

## Appraisal of encorafenib in dual or triple therapy for previously treated BRAF V600E mutation-positive metastatic colorectal cancer [ID1598]

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG)/Assessment Group (AG) representatives and representatives from Pierre Fabre Ltd.
2. The Chair asked all committee members, experts, ERG/AG representatives and NICE staff present to declare any relevant interests

	1. Dr Naureen Starling declared a direct financial interest as she has received support to attend advisory boards and received honoraria from comparator companies.
		1. It was agreed that this declaration would not prevent her from participating in this section of the meeting.
	2. Dr Harpeet Wasan declared a direct financial interest as he has attended advisory boards for Pierre Fabre and has done educational development work on BRAFV600E in colorectal cancer and the BEACON data. He also declared direct non-financial interests as he is the UK chief investigator of the BEACON study.
		1. It was agreed that this declaration would not prevent him from participating in this section of the meeting.
	3. Mr Mike Chambers declared a direct financial interest as he has been involved in running a training programme for Roche, who manufacture a potential comparator therapy. This did not involve consideration of any Roche products.
		1. It was agreed that this declaration would not prevent him from participating in this section of the meeting.
	4. Prior to the meeting Dr Nick Latimer declared a direct financial interest as he has provided advice to Pierre Fabre regarding the encorafenib trial.
		1. Due to this declaration, he withdrew from attending the meeting.
	5. No further conflicts of interest were declared for this appraisal.
	6. The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.
	7. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

### Part 2a – Closed session (company representatives, clinical and patient experts and members of the public were asked to leave the meeting)

1. The ERG remained present for part 2a. The committee discussed confidential information submitted as part of this appraisal.

### Part 2b – Closed session (ERG/AG representatives were asked to leave the meeting)

1. Agreement on the content of the Appraisal Consultation Document (ACD) was discussed by the committee.
2. The committee decision was based on consensus.

1. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

## Appraisal of lenalidomide for the maintenance treatment of multiple myeloma after autologous stem cell transplantation [ID475]

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG)/Assessment Group (AG) representatives and representatives from Celgene.
2. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests

	1. Professor Guy Pratt declared direct financial interests as he has received support from Celgene to attend educational events and advisory boards.
		1. It was agreed that this declaration would not prevent him from participating in this section of the meeting.
	2. Dr Karthik Ramasamy declared a direct financial interest as he has received funding from Celgene for research grants, speakers fees and advisory boards.
		1. It was agreed that this declaration would not prevent him from participating in this section of the meeting.
	3. Ms Shelagh McKinley declared an indirect financial interest as she is employed by Myeloma UK and they receive funding from several pharmaceutical companies, including Amgen, Janssen and Celgene.
		1. It was agreed that this declaration would not prevent her from participating in this section of the meeting.
	4. Prior to the meeting Mr Peter Wheatley Price declared a direct financial interest as he is employed by Takeda who manufacture potential competitor products.
		1. It was agreed that this declaration would prevent him from participating in this section of the meeting
	5. No further conflicts of interest were declared for this appraisal.
	6. The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.
	7. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

### Part 2a – Closed session (company representatives, clinical and patient experts, and members of the public were asked to leave the meeting)

1. The ERG remained present for part 2a. The committee discussed confidential information submitted as part of this appraisal.

### Part 2b – Closed session (ERG/AG representatives were asked to leave the meeting)

1. Agreement on the content of the Appraisal Consultation Document (ACD) was discussed by the committee.
2. The committee decision was based on consensus.
3. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.